Light-Activated drug combo targets tough lung cancers
NCT ID NCT06943664
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The approach combines a light-activated drug (ASP-1929) that targets and kills tumor cells with an immunotherapy (cemiplimab) that boosts the immune system. About 27 adults with stage IIIB-IV lung cancer that cannot be surgically removed will receive this combination to see if it shrinks tumors and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.